These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

303 related articles for article (PubMed ID: 28265599)

  • 1. Screening methods for identifying pharmacological chaperones.
    Shin MH; Lim HS
    Mol Biosyst; 2017 Mar; 13(4):638-647. PubMed ID: 28265599
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early Stage Discovery and Validation of Pharmacological Chaperones for the Correction of Protein Misfolding Diseases.
    Aubi O; Knappskog PM; Martinez A
    Methods Mol Biol; 2019; 1873():279-292. PubMed ID: 30341617
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacoperones as Novel Therapeutics for Diverse Protein Conformational Diseases.
    Tao YX; Conn PM
    Physiol Rev; 2018 Apr; 98(2):697-725. PubMed ID: 29442594
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacoperone drugs: targeting misfolded proteins causing lysosomal storage-, ion channels-, and G protein-coupled receptors-associated conformational disorders.
    Hou ZS; Ulloa-Aguirre A; Tao YX
    Expert Rev Clin Pharmacol; 2018 Jun; 11(6):611-624. PubMed ID: 29851355
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Protein Misfolding Diseases and Therapeutic Approaches.
    Yadav K; Yadav A; Vashistha P; Pandey VP; Dwivedi UN
    Curr Protein Pept Sci; 2019; 20(12):1226-1245. PubMed ID: 31187709
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Small-molecule modulation of cellular chaperones to treat protein misfolding disorders.
    Sloan LA; Fillmore MC; Churcher I
    Curr Opin Drug Discov Devel; 2009 Sep; 12(5):666-81. PubMed ID: 19736625
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular chaperone functions in protein folding and proteostasis.
    Kim YE; Hipp MS; Bracher A; Hayer-Hartl M; Hartl FU
    Annu Rev Biochem; 2013; 82():323-55. PubMed ID: 23746257
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Pharmacological chaperones: a potential therapeutic treatment for conformational diseases].
    Mendre C; Mouillac B
    Med Sci (Paris); 2010; 26(6-7):627-35. PubMed ID: 20619166
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacoperones: targeting therapeutics toward diseases caused by protein misfolding.
    Ulloa-Aguirre A; Zariñán T; Conn PM
    Rev Invest Clin; 2015; 67(1):15-9. PubMed ID: 25857579
    [TBL] [Abstract][Full Text] [Related]  

  • 10. On the design of broad based screening assays to identify potential pharmacological chaperones of protein misfolding diseases.
    Naik S; Zhang N; Gao P; Fisher MT
    Curr Top Med Chem; 2012; 12(22):2504-22. PubMed ID: 23339304
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mechanistic Insights into the Role of Molecular Chaperones in Protein Misfolding Diseases: From Molecular Recognition to Amyloid Disassembly.
    Hervás R; Oroz J
    Int J Mol Sci; 2020 Dec; 21(23):. PubMed ID: 33276458
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mechanisms of protein-folding diseases at a glance.
    Valastyan JS; Lindquist S
    Dis Model Mech; 2014 Jan; 7(1):9-14. PubMed ID: 24396149
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protein-misfolding diseases and chaperone-based therapeutic approaches.
    Chaudhuri TK; Paul S
    FEBS J; 2006 Apr; 273(7):1331-49. PubMed ID: 16689923
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of misfolding in rare enzymatic deficits and use of pharmacological chaperones as therapeutic approach.
    Pampalone G; Grottelli S; Gatticchi L; Lombardi EM; Bellezza I; Cellini B
    Front Biosci (Landmark Ed); 2021 Dec; 26(12):1627-1642. PubMed ID: 34994177
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Using pharmacological chaperones to restore proteostasis.
    Wang YJ; Di XJ; Mu TW
    Pharmacol Res; 2014 May; 83():3-9. PubMed ID: 24747662
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Extracellular chaperones and proteostasis.
    Wyatt AR; Yerbury JJ; Ecroyd H; Wilson MR
    Annu Rev Biochem; 2013; 82():295-322. PubMed ID: 23350744
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacoperones as a New Therapeutic Approach: In Vitro Identification and In vivo Validation of Bioactive Molecules.
    Ulloa-Aguirre A; Conn PM
    Curr Drug Targets; 2016; 17(13):1471-81. PubMed ID: 26953247
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vivo aspects of protein folding and quality control.
    Balchin D; Hayer-Hartl M; Hartl FU
    Science; 2016 Jul; 353(6294):aac4354. PubMed ID: 27365453
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacological chaperone approaches for rescuing GPCR mutants: Current state, challenges, and screening strategies.
    Beerepoot P; Nazari R; Salahpour A
    Pharmacol Res; 2017 Mar; 117():242-251. PubMed ID: 28027910
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Applying chaperones to protein-misfolding disorders: molecular chaperones against α-synuclein in Parkinson's disease.
    Chaari A; Hoarau-Véchot J; Ladjimi M
    Int J Biol Macromol; 2013 Sep; 60():196-205. PubMed ID: 23748003
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.